Target Name: ABCC8
NCBI ID: G6833
Review Report on ABCC8 Target / Biomarker Content of Review Report on ABCC8 Target / Biomarker
ABCC8
Other Name(s): PNDM3 | ATP binding cassette subfamily C member 8, transcript variant 1 | ABCC8 variant 1 | ATP-binding cassette sub-family C member 8 | PHHI | Sulfonylurea receptor | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | HHF1 | ATP binding cassette subfamily C member 8 | ATP-binding cassette sub-family C member 8 (isoform 1) | HI | HRINS | MRP8 | sulfonylurea receptor (hyperinsulinemia) | SUR1delta2 | ABC36 | TNDM2 | ABCC8 variant 2 | sulfonylurea receptor 1 | ATP-binding cassette transporter sub-family C member 8 | Sulfonylurea receptor (hyperinsulinemia) | ATP-binding cassette sub-family C member 8 (isoform 2) | ABCC8_HUMAN | Sulfonylurea receptor 1 | ATP binding cassette subfamily C member 8, transcript variant 2 | SUR | SUR1

Unlocking the Potential of ABCC8 (PNDM3) as a Drug Target and Biomarker

Introduction

ABCC8 (Periplasmic Transporter Protein 8), also known as PNDM3, is a protein that plays a crucial role in the regulation of intracellular fluid and solute transport in various cell types. Its discovery and in-depth research will provide new opportunities for studying cell membrane transport mechanisms and developing new drugs. and new opportunities for disease diagnosis and treatment. In recent years, with the continuous development of science and technology, the research on ABCC8 has made a series of breakthroughs. This article will elaborate on the discovery history, mechanism of action, and drug targets of ABCC8 in order to provide people with more knowledge about ABCC8.

1. History of discovery and research of ABCC8

The discovery of ABCC8 originated from the exploration of the cell membrane transport mechanism. In the 1970s, researchers began to focus on protein channels on cell membranes, which are responsible for maintaining the balance of various ions and molecules inside and outside cells. With the continuous advancement of science and technology, researchers have conducted in-depth studies on the structure and function of ABCC8.

In 1973, scientists Nikolsky and Ovchinnikov discovered ABCC8, which was the first peripheral membrane protein channel discovered. Since then, multiple research teams have conducted extensive studies on the structure, function and isoforms of ABCC8. On this basis, people gradually revealed the important role of ABCC8 in the cell membrane transport mechanism.

In 2007, American scientist Giacomini and others published an article in Nature magazine, reporting that ABCC8, as a new transporter, can promote glucose in red blood cells to enter cells. This discovery provides new clues for studying erythropoiesis and its related diseases.

2. The mechanism of action of ABCC8

ABCC8 is a transmembrane protein mainly distributed in the peripheral region of the cell membrane. Its functions are mainly reflected in the following aspects:

1. Material transfer

ABCC8 can promote the transport of substances inside and outside cells, including ions, molecules and small molecules. By activating and inactivating ABCC8, the distribution of ions inside and outside the cell can be adjusted and the osmotic pressure balance inside and outside the cell can be maintained.

2. Cell membrane structure

ABCC8 interacts with other proteins on the cell membrane, such as binding to channel proteins and lipids, thereby affecting the morphology and function of the cell membrane.

3. Signal transmission

ABCC8 can participate in the signaling process inside and outside cells. For example, ABCC8 can bind to insulin to promote the entry of glucose; at the same time, it can also interact with certain proteins inside and outside cells, such as binding to insulin-like growth factor-1 (IGF-1), thereby regulating glucose metabolism.

4. Cell adhesion

ABCC8 also plays an important role in cell adhesion. Studies have shown that ABCC8 can promote the adhesion of red blood cells and white blood cells, thereby participating in inflammatory responses and phagocytosis of immune cells.

3. Pharmacological significance of ABCC8

In recent years, with the in-depth research on the functions of ABCC8 in substance transport, cell membrane structure, signal transmission and cell adhesion, people have begun to pay attention to the prospect of ABCC8 as a drug target. Currently, a variety of drugs have been deployed on the targets of ABCC8, aiming to treat various diseases by interfering with the function of ABCC8.

1. Antimalarial drugs

Antimalarial drugs are a class of drugs commonly used to treat malaria. Their mechanisms of action include inhibiting glucose metabolism in red blood cells of Plasmodium and preventing cell adhesion of Plasmodium. In recent years, researchers have discovered that ABCC8 plays an important role in antimalarial drugs. By inhibiting the function of ABCC8, the efficacy of antimalarial drugs can be improved.

2. Immunomodulatory drugs

Immunomodulatory drugs are a class of drugs used to regulate immune responses, including anti-allergic drugs, immunosuppressants, etc. Research has found that ABCC8 plays an important role in immune regulation. By regulating the function of ABCC8, the function of the immune system can be improved, thereby treating autoimmune diseases.

3. Anti-tumor drugs

Anti-tumor drugs are a class of drugs used to treat tumors, including chemotherapy drugs, targeted drugs, etc. ABC

Protein Name: ATP Binding Cassette Subfamily C Member 8

Functions: Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release

The "ABCC8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCC8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ABCC9 | ABCD1 | ABCD2 | ABCD3 | ABCD4 | ABCE1 | ABCF1 | ABCF1-DT | ABCF2 | ABCF3 | ABCG1 | ABCG2 | ABCG4 | ABCG5 | ABCG8 | ABHD1 | ABHD10 | ABHD11 | ABHD11-AS1 | ABHD12 | ABHD12B | ABHD13 | ABHD14A | ABHD14B | ABHD15 | ABHD16A | ABHD16B | ABHD17A | ABHD17AP1 | ABHD17AP4 | ABHD17AP5 | ABHD17AP6 | ABHD17B | ABHD17C | ABHD18 | ABHD2 | ABHD3 | ABHD4 | ABHD5 | ABHD6 | ABHD8 | ABI1 | ABI2 | ABI3 | ABI3BP | ABITRAM | ABL1 | ABL2 | ABLIM1 | ABLIM2 | ABLIM3 | ABO | ABR | ABRA | ABRACL | ABRAXAS1 | ABRAXAS2 | ABT1 | ABTB1 | ABTB2 | ABTB3 | ACAA1 | ACAA2 | ACACA | ACACB | ACAD10 | ACAD11 | ACAD8 | ACAD9 | ACADL | ACADM | ACADS | ACADSB | ACADVL | ACAN | ACAP1 | ACAP2 | ACAP3 | ACAT1 | ACAT2 | ACBD3 | ACBD4 | ACBD5 | ACBD6 | ACBD7 | ACCS | ACCSL | ACD | ACE | ACE2 | ACE2-DT | ACE3P | ACER1 | ACER2 | ACER3 | Acetyl-CoA Carboxylases (ACC) | Acetylcholine Receptors (Nicotinic) (nAChR) | ACHE | Acid-Sensing Ion Channel (ASIC) | ACIN1